Advancing MRI: The Impact of Gadopiclenol in Clinical Practice

MRI continues to advance diagnostic precision, with gadolinium-based contrast agents (GBCAs) playing a critical role in enhancing image clarity. Gadopiclenol, a new high-relaxivity GBCA, offers improved diagnostic outcomes with potentially lower doses, making it essential for clinicians to understand its application in practice. There is a need to share experiences and insights on converting to Gadopiclenol for body, cardiac, and neuroradiology imaging to optimize its use. Additionally, understanding the safety and tolerability of this new agent is vital for its successful adoption. These presentations aim to equip healthcare professionals with the knowledge needed to improve patient care using this innovative contrast agent.